Market Place
Sourcing Support
FibroGen Appoints David DeLucia as Chief Financial Officer
16 Dec 2024 //
GLOBENEWSWIRE
FibroGen Reports Q3 2024 Financial Results
12 Nov 2024 //
GLOBENEWSWIRE
FibroGen to Report Q3 2024 Financial Results
04 Nov 2024 //
GLOBENEWSWIRE
FibroGen to Present at H.C. Wainwright 26th Annual Global Conference
03 Sep 2024 //
GLOBENEWSWIRE
FibroGen Reports Q2 2024 Results And Provides Business Update
06 Aug 2024 //
GLOBENEWSWIRE
FibroGen lays off 75% of US staff as cancer drug flunks 2 more trials
31 Jul 2024 //
FIERCE BIOTECH
FibroGen Reports Pamrevlumab Pancreatic Cancer Study Results
30 Jul 2024 //
GLOBENEWSWIRE
FibroGen to Report Second Quarter 2024 Financial Results
30 Jul 2024 //
GLOBENEWSWIRE
FibroGen To Host KOL Investor Event On FG-3246 In Prostate Cancer
18 Jun 2024 //
GLOBENEWSWIRE
FibroGen`s FG-3165 IND Cleared For Solid Tumor Treatment
03 Jun 2024 //
GLOBENEWSWIRE
FibroGen, Regeneron To Evaluate FG-3165, FG-3175 Plus LIBTAYO Combos
03 Jun 2024 //
GLOBENEWSWIRE
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
03 Jun 2024 //
GLOBENEWSWIRE
Fibrogen Fg-3246 Interim Phase 1b: Mcrpc Positive With Enzalutamide
23 May 2024 //
GLOBENEWSWIRE
FibroGen to Participate in Upcoming Investor Conferences
07 May 2024 //
GLOBENEWSWIRE
FibroGen Reports First Quarter 2024 Financial Results
06 May 2024 //
GLOBENEWSWIRE
FibroGen to Report First Quarter 2024 Financial Results
29 Apr 2024 //
GLOBENEWSWIRE
FibroGen`s FG-3246 + Enzalutamide Data at ASCO 2024
24 Apr 2024 //
GLOBENEWSWIRE
FibroGen, former employees settle dispute over alleged trade secrets theft
20 Apr 2024 //
FIERCE PHARMA
Prostate cancer ADC breaks FibroGen`s clinical losing streak
03 Apr 2024 //
FIERCE BIOTECH
FibroGen Announces Results from Ph 1 of FG-3246 for Prostate Cancer
02 Apr 2024 //
GLOBENEWSWIRE
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
26 Mar 2024 //
GLOBENEWSWIRE
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
11 Mar 2024 //
GLOBENEWSWIRE
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States
26 Feb 2024 //
GLOBENEWSWIRE
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
26 Feb 2024 //
GLOBENEWSWIRE
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
20 Feb 2024 //
GLOBENEWSWIRE
FibroGen To Host Part I of Virtual KOL Investor Event Series
05 Feb 2024 //
GLOBENEWSWIRE
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise
25 Jan 2024 //
GLOBENEWSWIRE
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat
09 Dec 2023 //
GLOBENEWSWIRE
FibroGen Reports Third Quarter 2023 Financial Results
06 Nov 2023 //
GLOBENEWSWIRE
FibroGen to Report Third Quarter 2023 Financial Results
23 Oct 2023 //
GLOBENEWSWIRE
FibroGen fails in DMD, continuing rotten run of phase 3 flops
31 Aug 2023 //
FIERCE BIOTECH
FibroGen Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
PRESS RELEASE
FibroGen CEO Conterno hits the exit after 3-year stint
25 Jul 2023 //
FIERCE PHARMA
FibroGen to Report Second Quarter 2023 Financial Results
24 Jul 2023 //
GLOBENEWSWIRE
FibroGen lays off 104 employees while ImmuneID restructures
19 Jul 2023 //
FIERCE BIOTECH
FibroGen reports third PhIII failure in idiopathic pulmonary fibrosis
27 Jun 2023 //
ENDPTS
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab
26 Jun 2023 //
GLOBENEWSWIRE
FibroGen faces more trouble in clinic as DMD drug fails phase 3
08 Jun 2023 //
FIERCE BIOTECH
FibroGen Announces Results from LELANTOS-1 Phase 3 Study of Pamrevlumab
07 Jun 2023 //
PRESS RELEASE
FibroGen to Present at Upcoming Investor Conferences
06 Jun 2023 //
PRESS RELEASE
FibroGen to Present at Jefferies Global Healthcare Conference
06 Jun 2023 //
GLOBENEWSWIRE
FibroGen, AZ`s anemia drug Evrenzo finally chalks up a win
19 May 2023 //
FIERCE PHARMA
FibroGen Announces Positive Results from Pivotal Phase 3 Trial of Roxadustat
18 May 2023 //
GLOBENEWSWIRE
FibroGen snags sole ADC asset from small biotech for $280M
09 May 2023 //
FIERCE BIOTECH
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
08 May 2023 //
GLOBENEWSWIRE
FibroGen Reports First Quarter 2023 Financial Results
08 May 2023 //
GLOBENEWSWIRE
FibroGen’s anemia pill falls short in blood cancer study
06 May 2023 //
BIOPHARMADIVE
FibroGen Announces Results for MATTERHORN, a Ph 3 Clinical Study of Roxadustat
05 May 2023 //
GLOBENEWSWIRE
FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 M
01 May 2023 //
GLOBENEWSWIRE
FibroGen to Report First Quarter 2023 Financial Results
24 Apr 2023 //
GLOBENEWSWIRE
Astellas depreciates FibroGen`s Evrenzo, nixes cell therapy deal
13 Apr 2023 //
FIERCE PHARMA
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2
03 Apr 2023 //
GLOBENEWSWIRE
FibroGen to Present at Cowen’s 43rd Annual Health Care Conference
27 Feb 2023 //
GLOBENEWSWIRE
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
27 Feb 2023 //
GLOBENEWSWIRE
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
17 Feb 2023 //
GLOBENEWSWIRE
FibroGen to Present at SVB Securities Global Biopharma Conference
02 Feb 2023 //
GLOBENEWSWIRE
FibroGen boosted to outperform at Raymond James on fibrosis candidate
26 Jan 2023 //
SEEKING ALPHA
FibroGen Reports Third Quarter 2022 Financial Results
07 Jan 2023 //
GLOBENEWSWIRE
Bank of America upgrades FibroGen to Buy on favorable risk
05 Jan 2023 //
SEEKING ALPHA
AZ`s partner FibroGen slaps former employees with trade secret theft lawsuit
06 Dec 2022 //
FIERCEPHARMA
